Portage Shares to Resume Trading; SalvaRx Acquisition Meeting Materials Mailed and Filed on SEDAR

TORONTO, Dec. 6, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) – Further to its news release of November 27, 2018, Portage Biotech Inc. ("Portage" or the "Company") is pleased to announce that its common shares will resume trading at the open on CSE tomorrow, December 7, 2018 with trading on OTC expected to resume shortly thereafter.

The mailing of shareholder meeting materials regarding the acquisition of SalvaRx Limited from SalvaRx Group plc has been completed. Copies of the meeting materials have been posted to SEDAR, the CSE website and Portage's corporate website.

Completion of the SalvaRx acquisition remains subject to shareholder and CSE approval.

Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company's future plans and operations, including management's assessment of the Company's expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.

SOURCE Portage Biotech Inc.

To read more Press Release articles, click here.